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Abstract: Osteoarthritis (OA) is considered one of the most common joint disorders worldwide
and its prevalence is constantly increasing due to the global longevity and changes in eating habits
and lifestyle. In this context, the role of gut microbiota (GM) in the pathogenesis of OA is still
unclear. Perturbation of GM biodiversity and function, defined as ‘gut dysbiosis’, might be involved
in the development of inflammaging, one of the main risk factors of OA development. It is well
known that physical exercise could play a key role in the prevention and treatment of several chronic
diseases including OA, and it is recommended by several guidelines as a first line intervention.
Several studies have shown that physical exercise could modulate GM composition, boosting intestinal
mucosal immunity, increasing the Bacteroidetes–Firmicutes ratio, modifying the bile acid profile,
and improving the production of short chain fatty acids. Moreover, it has been shown that low
intensity exercise might reduce the risk of gastrointestinal diseases, confirming the hypothesis of
a strict correlation between skeletal muscle and GM. However, up to date, there is still a lack of
clinical trials focusing on this research field. Therefore, in this narrative, we aimed to summarize the
state-of-the-art of the literature regarding the correlation between these conditions, supporting the
hypothesis of a ‘gut–joint axis’ and highlighting the role of physical exercise combined with adequate
diet and probiotic supplements in rebalancing microbial dysbiosis.
Keywords: gut microbiota; osteoarthritis; knee osteoarthritis; exercise; rehabilitation; gastrointestinal
microbiome; inflammaging; gut dysbiosis; diet; probiotics
1. Introduction
Osteoarthritis (OA) is the most common musculoskeletal disease, characterized by progressive
articular cartilage loss, formation of osteophytes, subchondral bone remodeling, and chronic joint
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inflammation [1]. OA mainly targets the hip and knee joints, although other skeletal sites (i.e., hands,
feet, spine) might be affected by this condition [2]. In particular, knee OA has a prevalence of 3.8% and
an incidence of 12% in the elderly population and occurs with joint pain and peri-articular muscle
weakness with a subsequent loss of function, increased disability, and reduction of health-related quality
of life [3,4]. Indeed, an early diagnosis of OA is crucial to set up a prompt, effective, and patient-oriented
treatment in order to prevent the age-related degenerative progression of this pathological condition [5].
The etiology of OA still remains unknown, but several risk factors have been identified such as
age, sex, obesity, diet, physical inactivity, abnormal loading of the joints, metabolic syndrome, and
inflammaging [6]. These two latter conditions are key components of OA onset and evolution,
and recently the microbial dysbiosis induced by quantitative and qualitative alterations of the gut
microbiota (GM) has been shown to sustain a chronic systemic low-grade inflammation, boosting the
main pathophysiological mechanisms underpinning OA [7].
The GM colonizes the entire gastrointestinal tract in a variable way and represents a real ecosystem,
weighing about 1.5 kg, and is composed of more than 1014 bacteria and more than 1000 species as well
as fungi, viruses, phages, parasites, and archea [8]. The most representative bacterial phyla of healthy
GM are Bacteroidetes and Firmicutes, followed by Actinobacteria, Fusobacteria, and Proteobacteria,
whereas the most representative genera are Bacteroides, Faecalibacterium, and Bifidobacterium [9].
GM has several functions such as nutrient absorption, maintenance of metabolic homeostasis, protection
from infections, and development of systemic and mucosal immunity [10,11]. Modifications in the GM
composition and metabolic activity might alter the immune response and host metabolism, leading to a
constant low-grade inflammation status with consequent development of musculoskeletal impairment
and frailty [12,13]. Furthermore, an expert consensus of the European Society for Clinical and Economic
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases has recently hypothesized that
GM is a major hidden risk factor for OA [7].
Several studies [14–16] have hypothesized the linkage between GM and osteoarthritis, taking into
account the potential correlations between serum levels of bacterial metabolites and joint degeneration,
however, at present, no systematic reviews have clearly described this topic.
Moreover, it has been recently hypothesized that physical exercise could also play a key role
in modifying GM composition [17] and at the same time, it could reduce the risk of gastrointestinal
diseases [18] such as inflammatory bowel disease, considering the emergent well-studied relationship
between muscle function and GM [13,19–21].
In this narrative review, we aimed to show the state-of-the-art about the previously hypothesized
correlations between GM alterations and OA in order to highlight new potential therapeutic directions
and types of intervention in the ‘gut–joint axis’ modulation.
2. Inflammaging
The association between OA and low-grade systemic and local inflammation is well known [22,23];
indeed, OA etiopathogenic mechanisms might include epigenetic alterations, mitochondrial
dysfunction, cellular senescence, and an age-related increased production of proinflammatory
mediators, resulting in a pro-inflammatory state, referred to as ‘inflammaging’ [24,25].
The presence of physiological TGF-β signaling is mandatory for the maintenance of correct
architecture and functioning of the articular cartilage [26]. The binding of TGF-β to its type II receptor
leads to the recruitment and phosphorylation of a type I receptor. In more detail, TGF-β could
signal both via the canonical type I receptor ALK5 (TGFBR1) or via the ALK1 (ACVRL1) receptor
in chondrocytes [27,28], and a positive correlation between the ALK1 expression levels and MMP13
expression in human OA cartilage has been previously demonstrated [27]. Therefore, an adequate
balance between ALK5 and ALK1 is mandatory to maintain cartilage homeostasis and the loss of
ALK5 signaling could result in the loss of cartilage integrity [29]. Indeed, the ALK1/ALK5 ratio
was demonstrated to be significantly increased in old C57Bl/6 mice compared to the young ones,
leading TGF-β signaling via the Smad1/5/8 route and chondrocyte differentiation into cells with an
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autolytic phenotype [27]. Furthermore, the chronic systemic inflammation in the geriatric population is
sustained by pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha
(TNF-a), whose serum levels commonly increase with age and are strongly correlated with the risk of
OA progression [30,31].
A direct correlation between aging and gut dysbiosis has been previously demonstrated and is
mainly characterized by an increase of pro-inflammatory anaerobes species and a consistent decrease
in anti-inflammatory species such as Faecalibacterium prauznitzii [32]. As evidence of these hypotheses,
it was later shown how longevity was inversely correlated with the alpha diversity of GM [33,34].
Finally, a typical feature of the aging process is the so-called “leaky gut syndrome”, an increased
intestinal permeability leading to the translocation of microbial products through the intestinal tight
junctions, resulting in endotoxemia and consequently in a pro-inflammatory status [35].
A possible link between gut dysbiosis and OA might be suggested by the correlation between the
serum levels of bacterial metabolites and joint degeneration [16]. This correlation has been described
in rodent models and humans affected by OA and is characterized by increased levels of circulatory
inflammatory markers including bacterially produced lipopolysaccharides (LPS) [36,37], suggesting
that microbiome-derived proinflammatory metabolites could play a putative role in OA pathogenesis.
Moreover, it has recently been shown that the subchondral dysbiosis resulting from the bacterial
translocation from GM to the joint, might support the development of OA [14]. Therefore, considering
gut dysbiosis and the leaky gut syndrome as cofactors in the development of inflammaging and
consequently of OA [38], it is likely to hypothesize the existence of a ‘gut–joint axis’ [7,14–16].
3. Obesity and Metabolic Syndrome
Diet is one of the major environmental factors contributing to the inter-individual differences
in physiologic GM microbiota composition [39,40]. Nutrients are fundamental not only for human
health, but also for the well-being of the trillions of microbes that compose the GM [41]. It has been
demonstrated that a high-fat diet was associated with a reduction of Bacteroidetes and an overgrowth of
opportunistic pathogens, promoting leaky gut syndrome, and enhancing systemic inflammation and
insulin resistance [42]. In contrast, the production of short-chain fatty acids (SCFAs) by healthy gut
bacteria such as Faecalibacterium, Succinivibrio, and Butyricimonas are able to induce an increase of
glucose uptake and insulin sensitivity [43]. Similarly, mice models have shown that SCFAs might have
a key role in maintaining bone homeostasis, downregulating the pro-inflammatory stimuli sustained by
regulatory T-cells and inhibiting bone resorption through a direct inhibition of osteoclast activity [44].
It is important to underline the role of an adequate diet and the use of dietary supplements
in the ‘active aging’ population [45,46]. Indeed, these two interventions combined with vitamin D
and amino acid supplementation and physical exercise could prevent several sequelae of the aging
process including sarcopenia, as shown by several studies in the literature [47–53]. Finally, it has been
demonstrated that there is a strong correlation between the adherence to a Mediterranean diet and a
lower risk of OA manifestation, mediated by the well-known anti-inflammatory activity of fibers [54].
Taken together, these findings suggest that a rich in fiber nutritional approach like the Mediterranean
diet combined with an adequate intake of micronutrients and physical exercise might be a cornerstone
to maintain good health status, particularly in older people.
The excess of adipose tissue is the result of a multifactorial process including genetic and
environmental factors with an imbalance between energy intake and expenditure, which might
lead to an increased risk of developing metabolic syndrome, characterized by hyperglycemia,
hypertriglyceridemia, dyslipidemia, and hypertension [55]. Recent studies have focused on the
association between body mass index (BMI) and GM composition [56,57]. In particular, Gao et al. [56]
investigated the fecal microbiome composition, profiled via 16S rRNA gene sequencing, on 551
participants categorized as underweight, normal, overweight, and obese, based on their BMI.
The authors showed that the bacterial community of the underweight group had a significantly
higher alpha diversity than other groups and, if stratified by gender, the alpha diversity across the
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BMI was maintained in females. Moreover, an enrichment of Fusobacteria was observed in the
fecal microbiota of obese males and an abundance of Actinobacteria in obese females. Finally, the
butyrate-acetoacetate CoA-transferase was enriched in obese subjects, resulting in an excess of energy
accumulation. These findings are in line with previous data in the literature showing a correlation
between the development of obesity-associated OA and gut dysbiosis [58,59] in animal models,
acting through an interaction with the innate immune system at both systemic and local levels [59].
Lipotoxicity is a typical feature of the metabolic syndrome that might promote the production of
proinflammatory cytokines with the consequent recruitment of mast cells, macrophages, and dendritic
cells in the adipose tissue, inducing a chronic low-grade inflammatory status [60].
Thus, considering these proinflammatory effects, obesity is considered one of the main risk factors
of OA [60], and it seems to also negatively influence muscle mass and function in older people [61,62].
In animal models, a high-fat/high-sucrose diet is able to promote knee joint damage, with an increase of
the intestinal permeability and a consequent increase of serum levels of LPS, supporting the hypothesis
of a linkage between gut dysbiosis, metabolic inflammation, and OA [7].
4. Gut Microbiota Modulation as Treatment of Osteoarthritis
The rebalancing of GM could have positive effects on the treatment of dysbiosis-related diseases;
in particular, GM modulation might be obtained through specific diets, probiotics (live organisms),
and prebiotics (indigestible and non-absorbable substances) supplementation [63–65]. Probiotics such
as Bifidobacterium and Lactobacillus exert their role by promoting gut health through the regulation
of pH levels and the colonization resistance [63–65]. On the other hand, prebiotics are able to stimulate
the activity and growth of several bacteria in the gastrointestinal tract, promoting the fermenting
process involved in the generation of SCFAs, which are considered key regulatory metabolites of gut
wellness [63–65].
In this context, it was hypothesized that GM modulation is able to modify the onset
and the progression of OA. Previous studies have shown that the administration of probiotics
significantly decreased the expression of pro-inflammatory cytokines in rat knee cartilage during
monoiodoacetate-induced OA [66]. Korotkyi et al. described the beneficial effects of a probiotic diet on
the expression of prostaglandin endoperoxide synthase-2 (PTGS2) and transforming growth factor
beta-1 (TGFb1), suggesting a potential perspective to improve the standard treatment of OA [66].
Furthermore, prebiotic supplementation in combination with aerobic exercise could prevent knee
joint damage, otherwise observed in an obesity-induced OA rat model [67]; in this study, the authors
highlighted that the integrity of the knee joint obtained in the prebiotic diet and physical activity group
was associated with the maintenance of GM homeostasis and the prevention of endotoxemia.
The main linking factor between GM and OA seems to be represented by the common chronic
low-grade inflammation, supporting a new OA phenotype, indicated as the ‘metabolic OA’ [15].
However, it has been hypothesized that the microbial community shifts induced by antibiotics, a
germ-free environment, or high-fat might have a key role in the development of OA, suggesting that
active microbiome modulation could be an effective therapeutic option to counter joint degeneration in
OA [16]. Finally, it has been suggested that dietary supplements and nutraceuticals might exert their
positive effects on health status in the elderly [45] through quantitative and qualitative modifications
of the GM [16].
Although previous studies have investigated the gut–joint axis in animal models, clinical studies
in humans are lacking and future perspectives should focus on a more detailed understanding of the
in vivo effects of probiotic and/or prebiotic administration in OA patients.
5. Physical Exercise and Gut Microbiota
Physical exercise plays a fundamental role in the prevention and treatment of several chronic
diseases including OA [68]; and it is recommended by several guidelines as a first line intervention
in the management of this condition [69–71]. Pathogenic mechanisms of the ‘gut–joint axis’ and the
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potential therapeutic role of physical exercise combined with diet and probiotics are depicted by
Figure 1.
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Recently, several studies have shown that physical exercise could modulate
GM composition [17,20,21], boost intestinal mucosal immunity [72], increase the
Bacteroidetes–Firmicutes ratio [73,74], modify the bile acid profile [75], and improve the
production of short chain fatty acids such as n-butyrate, acetate, and propionate [73,76]. In more detail,
it has to be noted that acetate and propionate are carried in the bloodstream to several organs as
substrates for local energy metabolism (i.e., gluconeogenesis) [77].
It has been previously shown that low intensity exercise might reduce the risk of gastrointestinal
diseases (i.e., colon cancer, diverticulosis, and inflammatory bowel disease), taking into account the
strict correlation between skeletal muscle and GM [13,17–21]. In more detail, physical activity might
modify the transient stool time and the contact time between the pathogens and the gastrointestinal
mucus layer, resulting in the gastrointestinal tract modifications above-mentioned [78].
How can the GM be modified in patients undergoing intense physical activity? At present, the
question remains unanswered. However, it has been demonstrated that GM can control oxidative
stress and inflammatory responses, improving metabolism and energy expenditure [75]. It is
important to underline that this is a two-way relationship, as shown by the key role of exercise
in reducing inflammatory infiltrate and protecting the morphology and integrity of the intestinal tract,
independently from the diet [79].
Does exercise have a role in contrasting inflammaging independently of an adequate diet? Evans
et al. showed that physical activity seems to prevent diet-induced obesity through a GM modulation
that results in a microbial composition similar to lean mice [73]. Moreover, it was recently demonstrated
that cardiorespiratory fitness, independent from diet, was correlated with increased GM diversity in
healthy humans [80]. At the same time, exercise might prevent obesity, also changing the percentage
of major bacterial phyla in obese-induced mice through high fat feeding, as shown by the inverse
correlation between the Bacteroidetes–Firmicutes ratio and the total distance run [73].
All these data were confirmed by a recent study performed by Campbell et al. that demonstrated
the presence of bacteria related to Faecalibacterium prausnitzii in mice undergoing a physical exercise
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protocol [79]. These bacteria commonly protect the digestive tract through butyrate production and
lowering the oxygen tension in the lumen, boosting a flavin/thiol electron shuttle. Furthermore, it
has been demonstrated that fit individuals showed a gut microbial profile enriched in Clostridiales,
Roseburia, Lachnospiraceae, and Erysipelotrichaceae bacteria, which are all butyrate-producers and
considered as indicators of gut health [80].
However, up to now, despite these evidences, the conundrum between physical exercise and
probiotic interventions in the modulation of GM is far from being understood in detail. Moreover, few
studies including the ones previously cited, took into account specific parameters of physical function.
Román et al. [81] have recently shown in a randomized trial that the administration of a probiotic
blend to cirrhotic patients could enhance the physical performance, according to the timed up and go
test (TUG); indeed, patients treated with probiotics showed an improvement in TUG (p = 0.015) and
gait speed (p = 0.02), and a trend toward a lower incidence of falls at the follow-up (p = 0.10). Table 1
describes all the studies that have investigated the correlation between physical exercise and GM.
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Table 1. Main studies included in the present narrative review that have investigated the correlation between physical exercise and gut microbiota (GM).
Authors, Year Study Design Population Intervention/Groups Outcomes Main Results Conclusions
Bermon S, et al.
2015 [75] Review Animals/Humans N/A N/A N/A
Exercise might modulate and
help to restore the GM when
altered by a high fat diet.
Campbell SC, et al.
2016 [76]
Randomized
controlled trial
Thirty-six, 6-week
old C57BL/6NTac
male mice
The mice were divided into our
groups:
1) lean sedentary (LS);
2) diet-induced obesity (DIO)
sedentary (OS);
3) lean exercise (LX);
4) DIO exercise (OX) groups.
Duodenum/ileum tissues were
fixed for
immune-histo-chemistry for
occludin, Ecadherin, and
cyclooxygenase-2 (COX-2).
Bacterial communities were
assayed in fecal samples using
terminal restriction fragment
length polymorphism (TRFLP)
analysis and pyrosequencing of
16S rRNA gene amplicons.
LS mice presented normal
histologic villi while OS mice
had similar villi height with
more than twice the width of
the LS animals. Both LX and
OX mice duodenum and ileum
were histologically normal.
COX-2 expression was the
greatest in the OS group,
followed by LS, LX and OX.
The TRFLP and
pyrosequencing indicated that
members of the Clostridiales
order were predominant in all
diet groups. Specific
phylotypes were observed with
exercise, including
Faecalibacterium prausnitzi,
Clostridium spp., and
Allobaculum spp.
Exercise has a strong influence
on gut integrity and host
microbiome.
Cerda B, et al.
2016 [72] Review Animals/Humans N/A N/A N/A
The release of hormones that
occurs during exercise could
modify the GM profile of
subjects performing physical
exercise at certain intensities or
durations.
Estaki M, et al.
2016 [80]
Cross-sectional
study
Healthy young
adults aged 18–35
years
A continuous incremental
ramp maximal exercise test on
an electronically braked cycle
ergometer to assess the Peak
oxygen uptake (VO2 peak).
According to the VO2 peak,
participants were categorized
into 3 groups:
1) low (LOW);
2) average (AVG);
3) high fitness (HI).
Peak oxygen uptake
(VO2peak), as an indicator of
physical fitness. Short-chain
fatty acids (acetic, propionic,
heptanoic, valeric, caproic, and
butyric acid) were analyzed
from the feces by gas
chromatography (GC) as
described previously
Using high-throughput
sequencing to analyze fecal
microbiota
GM diversity in healthy
humans is associated with
aerobic fitness. Moreover, the
GM profile of fit individuals
appears to favor butyrate
production (indicator of gut
health) through increases in
Clostridiales, Roseburia,
Lachnospiraceae, and
Erysipelotrichaceae genera.
Nutrients 2020, 12, 574 8 of 14
Table 1. Cont.
Authors, Year Study Design Population Intervention/Groups Outcomes Main Results Conclusions
Evans CC, et al.
2014 [73]
Randomized
controlled trial
Male C57BL/6
littermate mice (5
weeks)
Mice were divided into 4
groups:
1) low fat and sedentary
(LF/Sed);
2) low fat and exercise (LF/Ex);
3) high fat and sedentary
(HF/Sed);
4) high fat and exercise (HF/Ex).
LF/Ex and HF/Ex cages were
equipped with a wheel and
odometer to record Ex.
Fecal samples were collected at
baseline, 6 weeks and 12 weeks
and used for bacterial DNA
isolation. DNA was subjected
both to quantitative PCR using
primers specific to the 16S
rRNA encoding genes for
Bacteroidetes and Firmicutes
and to sequencing for lower
taxonomic identification using
the Illumina MiSeq platform
HF diet resulted in significantly
greater body weight and
adiposity as well as decreased
glucose tolerance that were
prevented by voluntary
exercise (p < 0.05). Sequencing
demonstrated exercise-induced
changes in the percentage of
major bacterial phyla at 12
weeks. A correlation between
total Ex distance and the ∆Ct
Bacteroidetes/∆Ct Firmicutes
ratio from qPCR demonstrated
a significant inverse correlation
(r2 = 0.35, p = 0.043).
The exercise induces a unique
shift in the GM that is different
from dietary effects. The
Bacteroidetes phylum
increased while it decreased
firmicutes in a manner that was
proportional to the distance run
in mice fed with high-fat diet.
GM changes might play a role
in exercise prevention of the
high-fat diet-induced obesity.
Hsu YJ, et al. 2015
[76]
Prospective
study
Male mice aged 12
weeks
The mice were divided into 3
groups:
1) specific pathogen-free (SPF);
2) germ-free (GF)
3) Bacteroides fragilis (BF)
gnotobiotic mice Swimming
was performed in plastic
containers.
Endurance Swimming, weight
of liver, muscle, brown adipose,
and epididymal fat pads.
Endurance swimming time
was longer for SPF and BF than
GF mice, and the weight of
liver, muscle, brown adipose,
and epididymal fat pads was
higher for SPF and BF than GF
mice.
GM status could be crucial for
exercise performance and its
potential action linked with the
antioxidant enzyme system in
athletes.
Mach N &
Fuster-Botella D.
2017 [75]
Review Animals/Humans N/A N/A N/A
Exercise might modulate and
help to restore the GM when
altered by a high fat diet.
Monda V, et al.,
2017 [17] Review Animals/Humans N/A N/A N/A
Exercise seems to be an
environmental factor that
might determine changes in
the GM composition with
possible benefits for the host.
Physical exercise is able to
enrich the microflora diversity
and to improve the
Bacteroidetes–Firmicutes ratio,
that might contribute to reduce
obesity-associated pathologies,
and gastrointestinal disorders
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Table 1. Cont.
Authors, Year Study Design Population Intervention/Groups Outcomes Main Results Conclusions
Morita E, et al.
2019 [74]
Prospective
study
Thirty-two
sedentary healthy
elderly women
The subjects were allocated
into two groups receiving
different exercise interventions,
trunk muscle training or
aerobic exercise training.
The GM composition in fecal
samples was determined before
and after the training period.
Clinical outcome measures
were:
a) daily physical activity, using
an accelerometer;
b) trunk muscle strength, by
the modified Kraus–Weber test;
c) cardiorespiratory fitness,
through 6-min walk test
(6MWT).
Exercise intervention modified
microbiota composition and
improved 6MWT.
Aerobic exercise targeting an
increase of the time spent in
brisk walking could increase
intestinal Bacteroides
correlated with an improved
cardiorespiratory fitness in a
cohort of healthy elderly
women.
Picca A, et al.
2020 [21]
Cross-sectional
study
Thirty-five
participants
community-dwellers
aged more than 70
years.
The presence of PF&S was
established according to
physical frailty, based on:
a) Short Physical Performance
Battery between 3 and 9;
b) low appendicular muscle
mass;
c) absence of mobility disability.
They were divided into 2
groups: 18 older adults with
physical frailty and sarcopenia
(PF & S), mean aged 75.5 ± 3.9
years, and 17 non-PF & S
controls, mean aged 73.9 ± 3.2
years
A multi-marker immunoassay
was used to measure
circulating levels of a panel of
inflammatory markers. Serum
concentrations of 37 amino
acids and derivatives were
determined by
ultraperformance liquid
chromatography/ mass
spectrometry. Total genome
DNA was extracted from fecal
samples using the QIAmp Fast
DNA Stool mini kit (Qiagen,
Germany).
PF&S participants showed
higher serum concentrations of
aspartic acid, lower circulating
levels of concentrations of
threonine and macrophage
inflammatory protein 1,
increased abundance of
Oscillospira and Ruminococcus
microbial taxa, and decreased
abundance of Barnesiellaceae
and Christensenellaceae.
The Authors showed a specific
relationship among GM,
systemic inflammatory
mediators, and metabolic
alterations in older adults with
PF&S.
Ticinesi A, et al.
2019 [20] Review Animals/Humans N/A N/A N/A
The presence of a gut-muscle
axis involved in the
pathophysiology of PF & S is
biologically plausible and is
supported by a limited number
of animal and human studies.
However, the Authors
conclude affirming that the
causal link was still uncertain.
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6. Conclusions
This narrative review showed how several studies supported the hypothesis of a ‘gut–joint axis’
and in this context, physical exercise interventions combined with different nutritional approaches
might play a key role in rebalancing microbial dysbiosis and could be considered as adjuvant treatments
in dysbiosis-associated diseases.
However, these findings remain anecdotal and data on quantitative and qualitative microbiome
composition in OA patients are still lacking and more research efforts are needed to understand the
shared pathways and synergies between exercise, diet, and probiotics in GM modulation. Thus, to
address these issues, future research should focus on several aspects: (1) a detailed assessment of
the correlation between GM, prebiotics/probiotics, and nutraceuticals to create effective therapeutic
interventions to counteract OA pathogenesis and progression; (2) investigate new potential biomarkers
related to inflammaging and gut dysbiosis (i.e., inflammatory cytokines, matrix metalloproteases,
and LPS) that are able to predict OA onset and monitor therapeutic intervention efficacy; and (3) to
investigate how new cutting edge GM therapeutic interventions might impact host biology and might
protect from OA onset.
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